Previously, we demonstrated that selectively blocking sCTLA-4 boosted antigen-specific immune responses and further, generated effective anti-tumour immunity in the B16F10 model of metastatic melanoma, which was comparable to that achieved with pan-specific anti-CTLA-4 mAb (36). Here, CTLA4 is linked to neoplasm.